Business Wire - The global leader in news distribution
Updated: 29 min 4 sec ago
SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--Versant Ventures today announced an infusion of $700 million through two new funds. These include a primary global fund, Versant Venture Capital VII, which closed at its hard cap of $600 million. In addition, Versant raised $100 million for a Canadian companion fund called Versant Voyageurs I. Both funds exceeded their initial targets and were supported by existing investors and a select number of new
TORONTO & VANCOUVER, British Columbia & MONTREAL--(BUSINESS WIRE)--Versant Ventures today announced that it raised USD100 million for a Canadian fund called Versant Voyageurs I. Voyageurs will be deployed across five to eight startup companies with Canadian operations. The fund will be invested side by side with Versant’s primary biotech funds, including today’s newly announced USD600 million Versant Venture Capital VII. The objective of Voyageurs is to establish Canadian companies with the nec
Titan Medical Expands Global Patent Portfolio for Single-Port Robotic Surgery with Seven Grants and Notices of Allowance
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (TSX:TMD) (Nasdaq:TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces seven new patent grants and notices of allowance related to its single-port robotic surgery technology, including patents covering multi-articulating instruments, robotic system control and user interfaces. Including these new patents and notice
AmorChem Spins out Its Muco-Adhesive Nanoparticle Delivery Platform into MyX Therapeutics, with 450,000$ Seed Investment.
MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MyXdelivery?src=hash" target="_blank"gt;#MyXdeliverylt;/agt;--AmorChem announces today the creation of MyX Therapeutics Inc, its sixth spin-off company focusing on MyX-001, a biodegradable muco-adhesive nanoparticle delivery platform, capable of sustained drug releases for ophthalmic use and other mucosa-based deliveries. All rights to the MyX-001 technology initially held by AmorChem have been transferred to MyX Therapeutics, with a first seed investment of 450,000$. This capital will allow MyX to clinch its first deals with co
Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.” The Company's patent secures market exclusivity for its key product. Regentys ECMH™ is a novel application of extracellu
NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced an investment in Québec-based cannabis producer, ROSE LifeScience Inc. (“ROSE”) and an exclusive sale, supply, distribution and marketing agreement between High Park Farms Ltd. (“High Park”), a wholly-owned subsidiary of Tilray, and ROSE. Tilray will subscribe for 41 Class “A” Common shares (12%) in the capital of ROSE for a subscription amount of C$7
TORONTO--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/healthscience?src=hash" target="_blank"gt;#healthsciencelt;/agt;--The national call for applications from health science companies to present at the OBIO 2019 Niagara Investment Summit is now open, Feb 20-22, 2019.
VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CME?src=hash" target="_blank"gt;#CMElt;/agt;--Information industry veteran to guide life sciences revenue acquisition efforts for the company’s healthcare professional content engagement platform
Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting of Innovations in Wound Healing
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Olaregen Therapeutix, a regenerative medicine company contracted to become a subsidiary of Generex, was a co-sponsor of the Annual Meeting of Innovations in Wound Healing (IWH) held December 7 – 9, 2018 in Key West, Florida and attended by over 150 influential clinicians and researchers. Olaregen also hosted an Advisory Board Meeting attended by esteemed influencers in the specialties of Vascular
Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
BOSTON--(BUSINESS WIRE)--Health Canada grants market authorization for ORKAMBI® (lumacaftor/ivacaftor) for children with cystic fibrosis aged 2 to 5 years old.
NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced the formation of its International Advisory Board, an esteemed group of business and government leaders who will provide guidance to Tilray’s executive team and Board of Directors as the company pursues its aggressive global growth strategy. “We are honored to welcome this impressive group of distinguished leaders to the Tilray team,” says Brendan Ken
LAVAL, Quebec--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Altasciences?src=hash" target="_blank"gt;#Altascienceslt;/agt;--Altasciences recently completed an important First-in-Human (FIH), Phase I, integrated adaptive clinical trial, including single and multiple ascending doses (SAD and MAD), Project Management, Bioanalysis, and Medical Writing, for sponsor Bellus Health. Altasciences’ contributions to the positive top-line results were significant. From recruitment of 90 subjects to management of all relevant aspects of this important FIH trial, Altasciences used a flexible and ad
TORONTO--(BUSINESS WIRE)--Halo Labs announces strategic partnership with a Bephelo Bioscience, a cannabis company in Lesotho Africa
OTTAWA, Ontario--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/HR?src=hash" target="_blank"gt;#HRlt;/agt;--The award showcases employees who have contributed to the growth of Canada’s bio-economy while highlighting biotech companies as Employers of Choice.
BASEL, Switzerland & TORONTO--(BUSINESS WIRE)--Black Diamond Therapeutics, a biotechnology company developing a new type of precision medicine for cancer, came out of stealth mode today with a $20 million Series A financing exclusively from founding investor Versant Ventures. Black Diamond is the first company launched out of Ridgeline, Versant’s Discovery Engine based in Basel, Switzerland, and has a unique platform capable of prosecuting allosteric mutant oncogenes. Oncogenes are activated by
Analytics 4 Life® and Actelion Enter Research Agreement to Develop New Diagnostics for Pulmonary Hypertension
RESEARCH TRIANGLE PARK, N.C. & TORONTO--(BUSINESS WIRE)--Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, and Actelion Pharmaceuticals Ltd., today announced a collaborative agreement to investigate the use of Analytics 4 Life’s diagnostic imaging technology in pulmonary hypertension. The first 500-person clinical study has been initiated for this serious, life-threatening condition affecting millions of people worldwide. Analytics 4 Life seeks to u
Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today providing results of a Phase 1 clinical trial (the “trial”) testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers. The THC trial, previously announced on October 24, 2018, involved 12 overnight-fasting, healthy subjects with prior cannabis experience. Each subject randomly received one 5mg dose of cannabis oil orally and an
GUILFORD, Conn.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BIOAF&src=ctag" target="_blank"gt;$BIOAFlt;/agt; lt;a href="https://twitter.com/hashtag/BBB?src=hash" target="_blank"gt;#BBBlt;/agt;--Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Deborah A. Rathjen, B.Sc. (Hons), Ph.D.,
VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoSphere signs key agreement for distribution of cannabis and CBD products in Mexico, as country prepares for legalization.
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium
VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, presented IND-enabling data for ZW49, a novel biparatopic HER2-targeted ADC, at the San Antonio Breast Cancer Symposium in San Antonio, TX. “These data highlight the potential efficacy of ZW49 versus leading HER2 ADCs and demonstrate the power of combining our therapeutic platforms to achieve greater efficacy and tolerability, thereby increasin